ArticlemAbs

Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies.

Lone Fjord-Larsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.